{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Blood Cancer Talks","title":"Episode 43. Essential Thrombocythemia with Dr. Raajit Rampal","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/814b2035\"></iframe>","width":"100%","height":180,"duration":2128,"description":"In this episode, we discuss the diagnosis and management of Essential Thrombocythemia with Dr. Raajit Rampal. Here are the shownotes:\n1.     IPSET (revised) system, risk categories are defined by the presence of a prior thrombosis, age, and JAK2 mutation status:\n·        Very low risk: No prior thrombosis, age ≤60 years, JAK2-unmutated\n·        Low risk: No prior thrombosis, age ≤60 years, JAK2-mutated\n·        Intermediate risk: No thrombosis, age >60 years, JAK2-unmutated\n·        High risk: History of thrombosis (any age/genotype), or age >60 years with JAK2 mutation\nhttps://ashpublications.org/blood/article/120/26/5128/30914/Development-and-validation-of-an-International\n                      \n2.    The MIPSS-ET provides points for:\n·        Age > 60 years (3 points)\n·        Adverse mutation (SF3B1/SRSF2/U2AF1/TP53) (2 points)\n·        Male sex (1 point)\n·        White blood cell count ≥11 × 10^9/L (1 point)\n·        https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.16380?sid=nlm%3Apubmed\n \n3.    Aspirin\n \no   Is there a benefit of twice-daily aspirin dosing, especially in high-risk or JAK2-mutant disease?\nhttps://ashpublications.org/blood/article/136/2/171/454293/A-randomized-double-blind-trial-of-3-aspirin\n \n4.     Cytoreduction in High-risk ET\n \nHydroxyurea: https://www.nejm.org/doi/full/10.1056/NEJM199504273321704\n \nPegylated interferon alfa\n \nMPD-RC 112 Mascarenhas J et al. A randomized phase 3 trial of interferon- α vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood . 2022) \nhttps://ashpublications.org/blood/article/139/19/2931/483404/A-randomized-phase-3-trial-of-interferon-vs\n \nAnagrelide in ET\nhttps://ashpublications.org/blood/article/121/10/1720/31186/Anagrelide-compared-with-hydroxyurea-in-WHO\n \n5.    Ruxolitinib  \nIn a randomized study phase 2 study (MAJIC-ET), ruxolitinib treatment did not deliver better rates of hematological response than best-available therapy, although symptoms did improve. \n \n·        MAJIC-ET study...","thumbnail_url":"https://img.transistorcdn.com/sqlYzk0Oxhchi1Lmft_9Md8dG97D7hyy2rwRG7COuc0/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzMyMDc4LzE2NTcz/MTQxMDUtYXJ0d29y/ay5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}